Brainstorm Cell Therapeutics Inc. (BCLI)

NASDAQ: BCLI · IEX Real-Time Price · USD
1.66
+0.01 (0.61%)
At close: Dec 2, 2022 4:00 PM
1.64
-0.02 (-1.20%)
After-hours: Dec 2, 2022 6:35 PM EST
0.61%
Market Cap 60.29M
Revenue (ttm) n/a
Net Income (ttm) -25.45M
Shares Out 36.49M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,809
Open 1.6
Previous Close 1.65
Day's Range 1.6 - 1.68
52-Week Range 1.09 - 4.7
Beta -0.31
Analysts Buy
Price Target 7.14 (+338.0%)
Earnings Date Nov 14, 2022

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing Nu... [Read more]

Industry Biotechnology
Founded 2000
CEO Chaim Lebovits
Employees 43
Stock Exchange NASDAQ
Ticker Symbol BCLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BCLI stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 338.04% from the latest price.

Price Target
$7.14
(338.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc....

New York, New York--(Newsfile Corp. - November 30, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI...

3 days ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc....

New York, New York--(Newsfile Corp. - November 19, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI...

2 weeks ago - Newsfile Corp

BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update

BrainStorm to request Type A meeting with FDA to facilitate NurOwn's advancement following receipt of a refusal to file letter regarding the company's new Biologics License Application Conference call a...

2 weeks ago - PRNewsWire

BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for N...

NEW YORK , Nov. 10, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has ...

3 weeks ago - PRNewsWire

BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will...

3 weeks ago - PRNewsWire

BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting

New post-hoc analyses that account for ALSFRS-R floor effects add to the robust body of evidence supporting a clinically meaningful treatment effect with NurOwn® in ALS NEW YORK , Nov. 7, 2022 /PRNewswi...

3 weeks ago - PRNewsWire

BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

Biomarker analyses show robust increases in cerebrospinal fluid neuroprotective biomarkers following NurOwn treatment NEW YORK , Oct. 20, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ...

1 month ago - PRNewsWire

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

NurOwn® drove biomarker responses, affecting pathways related to neurodegeneration, neuroinflammation, and neuroprotection, that were consistent in participants with both advanced ALS and less advanced ...

1 month ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS T...

Data demonstrate NurOwn's safety and provide preliminary evidence of efficacy in patients with progressive multiple sclerosis Biomarker analyses show consistent treatment effects in neuroinflammation an...

2 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update

BrainStorm to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NurOwn ®  for the treatment of ALS New clinical analyses reinforce the conclusions from NurO...

3 months ago - PRNewsWire

BrainStorm to Announce Second Quarter Results and Provide a Corporate Update

NEW YORK , Aug. 1, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a co...

4 months ago - PRNewsWire

BrainStorm Announces Presentations at June 2022 Scientific Conferences

Analyses accounting for ALSFRS-R floor effect in ALS yields new results to be presented at the ENCALS meeting in Edinburgh, Scotland Clinical, biomarker and preclinical data from NurOwn® Phase 2 clinica...

6 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update

BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access to NurOwn® Strengthened executive team in preparation...

6 months ago - PRNewsWire

BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal

Netta Blondheim-Shraga, PhD Appointed as VP R&DAntal Pearl-Lendner, Adv. Appointed as Chief Legal Counsel  NEW YORK , May 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a lea...

6 months ago - PRNewsWire

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes NEW YORK , May 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics...

6 months ago - PRNewsWire

BrainStorm Announces Upcoming Scientific Conference Presentations

Data on MSC-NTF exosome technology at ISCT 2022 and ISEV 2022 conferences NurOwn® CFS biomarker analysis to be presented at ALS Drug Development Summit NEW YORK , May 3, 2022 /PRNewswire/ -- BrainStorm ...

7 months ago - PRNewsWire

BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update

NEW YORK , May 2, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will h...

7 months ago - PRNewsWire

Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and ho...

NEW YORK, March 28, 2022 /PRNewswire/ -- Brainstorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disease, announced today that the company President ...

8 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update

NEW YORK, March 28, 2022 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financi...

8 months ago - PRNewsWire

BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update

NEW YORK, March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will...

8 months ago - PRNewsWire

BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Co...

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptan...

9 months ago - PRNewsWire

Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Bra...

9 months ago - PRNewsWire

BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph K...

10 months ago - PRNewsWire

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Ke...

10 months ago - PRNewsWire

FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program

NEW YORK, Dec. 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing ext...

11 months ago - PRNewsWire